TLR9 and melanoma: Other examples of TLR-9 agonists include SD-101, which is currently under investigation in combination with pembrolizumab for patients with advanced melanoma [148], and vidutolimod (CMP-001), which has a distinctive structure, resembling an immunogenic film similar to a virus, triggering the production of antibodies.